Security key
87975F104
Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO)
CUSIP: 87975F104
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Common Stock, no par value
- Total 13F shares
- 2,285,727
- Total 13F value
- $3,040,166
- Share change
- -46,337
- SEC-reported price per share
- $1.33
- Number of holders
- 33
- Value change
- -$68,478
- Number of buys
- 12
- Number of sells
- 13
- Shares outstanding
- 34,382,284
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
33
Top holders
10
TELO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Telomir Pharmaceuticals, Inc. SEC filings
Telomir Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 87975F104
Recent filing periods:
Ownership snapshot
Top reported holders of TELO - Telomir Pharmaceuticals, Inc. - Common Stock, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
John Paul DeJoria
Disclosed value leader
MIRA PHARMACEUTICALS, INC.
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G
3/4/5
13F
Lead comparable stake: 9.4%
13D/G row: John Paul DeJoria
Showing 1-6 of 15 holder rows.
Quick read
John Paul DeJoria leads the comparable SEC ownership view at 9.4%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens John Paul DeJoria's linked filing trail.
Comparable ownership
Top 5
John Paul DeJoria
9.4%
MIRA PHARMACEUTICALS, INC.
10%
VANGUARD GROUP INC
3.2%
BlackRock, Inc.
0.85%
MILLENNIUM MANAGEMENT LLC
0.65%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| John Paul DeJoria |
13D/G
John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity
|
9.4%
|
$4,315,850
3,245,000 shares
|
+$1,955,233 | 31 Dec 2025 |
| MIRA PHARMACEUTICALS, INC. |
3/4/5
10%+ Owner
|
10%
|
$4,823,943
3,521,127 shares
|
— | 29 Sep 2025 |
| VANGUARD GROUP INC |
13F
Company
|
3.2%
|
$1,531,435
1,101,752 shares
|
— | 30 Sep 2025 |
| BlackRock, Inc. |
13F
Company
|
0.85%
|
$405,092
291,433 shares
|
— | 30 Sep 2025 |
| MILLENNIUM MANAGEMENT LLC |
13F
Company
|
0.65%
|
$309,142
222,404 shares
|
— | 30 Sep 2025 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.57%
|
$272,634
196,030 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
33
Shares
2,285,727
Rows available
33
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
31
Q4 2025 holders
33
Holder diff
2
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend